Lp(a) lipoprotein redux--from curious molecule to causal risk factor.

Sekar Kathiresan

Abstract readCommentEditorial

In one paragraph

Article in The New England journal of medicine, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it

0cells of the map it votes in

6citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

Association of Lipoprotein(a) and ApoB/ApoA1 Ratio with SYNTAX Score in Premature Myocardial Infarction: an Age-Stratified Study from Northeast India.Maedica · 2026
Article
The Potential Role of Genomic Medicine in the Therapeutic Management of Rheumatoid Arthritis.Journal of clinical medicine · 2019
Review
Lipoprotein (a): Coming of Age at Last.Journal of lipid research · 2016
Review
Targeting lipoprotein (a): an evolving therapeutic landscape.Current atherosclerosis reports · 2015
Review
Dyslipidaemia: PCSK9 antibodies: a dividend of the genomics revolution.Nature reviews. Cardiology · 2013
Article
Safety and efficacy of laropiprant and extended-release niacin combination in the management of mixed dyslipidemias and primary hypercholesterolemia.Drug, healthcare and patient safety · 2010
Article

4 · The record

Corrections and comments

Commented on by
Genetic variants in Lp(a) lipoprotein and coronary disease.2010
Comment on
Genetic variants associated with Lp(a) lipoprotein level and coronary disease.2009

5 · Who and what money

Authors and funding

1 author.

Sekar Kathiresan

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Genetic Predisposition to DiseasePolymorphism, Single NucleotideCoronary DiseaseGenetic MarkersGenotypeHumansKringlesLipoprotein(a)Oligonucleotide Array Sequence AnalysisRisk FactorsGenetic MarkersLipoprotein(a)

Identifiers

PMID20032327

DOI10.1056/NEJMe0910792

What Socratic holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.